Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care
A Prospective, Randomized, Controlled Trial Comparing Cytal Wound Matrix 1-Layer to Standard of Care (SOC) in the Management of Diabetic Foot Ulcers (DFUs)
Sponsor: Integra LifeSciences Corporation
Terminated
Sponsor Discretion
Other terminated trials from Integra LifeSciences Corporation
- Peripheral Nerve Injuries · Jun 2024
- Digital Nerve Injury · Phase NA · May 2024
- Ventral Incisional Hernia · Phase NA · Jun 2021
- Ventral Incisional Hernia · Jun 2021
- Wounds · Jan 2020
More terminations from Integra LifeSciences Corporation
A NA clinical study on Diabetes and Diabetes Mellitus, Type 1, this trial is terminated or withdrawn. The trial is conducted by Integra LifeSciences Corporation and has accumulated 13 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Dec 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Terminated NA
-
Mar 2021 — Sep 2021 [monthly]
Terminated NA
-
Jan 2021 — Mar 2021 [monthly]
Terminated NA
-
Oct 2020 — Jan 2021 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Feb 2020 — Oct 2020 [monthly]
Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Recruiting NA
-
Aug 2019 — Jan 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Aug 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Integra LifeSciences Corporation
For direct contact, visit the study record on ClinicalTrials.gov .